Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Venlafaxine
Drug ID BADD_D02346
Description Venlafaxine (Effexor) is an antidepressant within the serotonin-norepinephrine reuptake inhibitor (SNRI) class of medications. It exerts its effects primarily by blocking the transporters involved in the reuptake of the neurotransmitters serotonin and norepinephrine, therefore leaving more active neurotransmitter in the synapse. Venlafaxine is officially approved for use in the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder. As of 2014, Canadian clinical practice guidelines recommend venlafaxine as a first-line option for treatment of generalized anxiety, social anxiety, panic disorder, major depressive disorder (MDD), and consider it a second-line option for management of obsessive-compulsive disorder (OCD) [A177226,A177235]. Venlafaxine is also used off-label for prophylaxis of migraine headaches [A177229], for reduction of vasomotor symptoms associated with menopause [A177238], and for management of neuropathic pain (although there is only minimal evidence of efficacy for this condition) [A177232].
Indications and Usage For the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (social phobia), panic disorder with or without agoraphobia, vasomotor symptoms in women with breast cancer and in postmenopausal women, and neuropathic pain.
Marketing Status Prescription; Discontinued
ATC Code N06AX16
DrugBank ID DB00285
KEGG ID D08670
MeSH ID D000069470
PubChem ID 5656
TTD Drug ID D0P1UX
NDC Product Code 71209-025; 46708-433; 43602-392; 23155-246; 68001-156; 46708-431; 50268-801; 43598-944; 70518-3269; 65162-305; 62332-010; 68084-856; 57664-396; 16714-655; 57664-394; 51407-454; 68001-497; 63187-414; 43602-393; 50090-4715; 72865-200; 67877-727; 50090-2210; 62332-008; 63187-929; 65162-302; 68382-021; 71335-0778; 23155-250; 72865-198; 72865-199; 61919-495; 0527-2606; 51407-457; 71610-606; 60760-713; 51407-455; 51407-456; 71209-088; 43598-943; 67877-729; 50268-800; 63187-752; 31722-123; 71335-0449; 46708-434; 68001-159; 51407-453; 43063-633; 16714-659; 50268-798; 68001-498; 23155-247; 65162-306; 61919-351; 57664-392; 68084-896; 57664-395; 68001-157; 50090-4805; 61919-938; 71209-027; 67877-726; 65162-307; 23155-249; 31722-125; 70518-1245; 16714-656; 71209-029; 71209-087; 62332-012; 57664-393; 68382-020; 68382-018; 43602-395; 68382-019; 46708-432; 50090-4865; 31722-126; 67877-728; 16714-658; 68001-496; 23155-248; 16714-657; 71209-089; 70518-1547; 70518-2751; 50268-799; 68001-160; 62332-011; 43602-394; 31722-124; 50090-2408; 68084-844; 71209-026; 62332-009; 65162-300; 72865-197; 68071-4341; 71209-028; 68382-101; 46708-430; 61919-535; 68001-158; 68001-499
Synonyms Venlafaxine Hydrochloride | Hydrochloride, Venlafaxine | Cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, hydrochloride | 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexanol HCl | Wy 45030 | Wy-45030 | Wy45030 | Wy-45,030 | Wy 45,030 | Wy45,030 | Sila-Venlafaxine | Sila Venlafaxine | Effexor | Trevilor | Vandral | Efexor | Venlafaxine | Dobupal
Chemical Information
Molecular Formula C17H27NO2
CAS Registry Number 93413-69-5
SMILES CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Metabolic disorderActivity-regulated cytoskeleton-associated proteinQ9WV31Not Available14580947; 15838995; 15087240
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cystitis11.01.14.001; 20.03.02.002--
Deafness04.02.01.0010.000373%Not Available
Death08.04.01.001--
Death neonatal18.04.01.002; 08.04.01.0020.000155%
Decreased interest19.15.02.0040.000298%Not Available
Dehydration14.05.05.001--
Delirium19.13.02.0010.001863%
Delusion19.10.01.0010.001118%
Dementia19.20.02.001; 17.03.01.0010.000373%Not Available
Dementia Alzheimer's type19.20.03.001; 17.03.06.0010.000149%Not Available
Dental caries07.09.01.0010.000149%
Dependence19.07.02.0030.000373%Not Available
Depressed level of consciousness17.02.04.0020.001639%
Depressed mood19.15.02.0010.002384%Not Available
Depression19.15.01.0010.009462%
Derealisation19.10.02.0010.000447%Not Available
Dermatitis23.03.04.002--Not Available
Dermatitis allergic23.03.04.003; 10.01.03.0140.000596%Not Available
Dermatitis bullous23.03.01.002--
Dermatitis contact23.03.04.004; 12.03.01.040; 10.01.01.003--Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Developmental coordination disorder19.22.01.001; 17.02.02.0110.000058%Not Available
Developmental delay08.01.03.0370.000149%Not Available
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diabetic ketoacidosis14.07.03.001; 05.07.03.001--Not Available
Diarrhoea07.02.01.001--
Diarrhoea haemorrhagic24.07.02.004; 07.02.01.0020.000224%Not Available
Dilatation ventricular02.04.02.0260.000136%Not Available
Diplopia17.17.01.005; 06.02.06.0020.000671%Not Available
Discomfort08.01.08.0030.000969%Not Available
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 40 Pages